MAPT and insomnia measurement: Suvorexant, for example, is approved for treating insomnia in mild-to-moderate AD patients [11, 78], has shown cognitive benefits in AD and tauopathy mouse models [79, 80], and reduces tau phosphorylation and Aβ in cognitively unimpaired participants [81], indicating potential preventative or disease modifying effects for AD.